Autolus Therapeutics (NASDAQ:AUTL – Get Rating) had its price target decreased by Wells Fargo & Company from $8.00 to $6.00 in a research report released on Friday, The Fly reports. Several other equities analysts also recently issued reports on AUTL. Needham & Company LLC reissued a buy rating and set a $7.00 price target on […]